The aim of the Genomics Core Technology Unit (GCTU) is to enhance research by providing access to the latest genomics technology.
A significant investment in state-of-the-art equipment enables us to support a range of genomics applications, with a particular focus on Next-Generation Sequencing (NGS). We provide an increasing range of off-the shelf NGS services and will also work with research teams to develop bespoke projects that exploit the power of NGS applications to enhance research outputs.
The GCTU is a not-for-profit service provider for the research community and is equipped with state-of-the-art next generation sequencing platforms. Coupled with complementary robotics, sequence capture and array capabilities, we offer optimum, tailor-made solutions across a wide range of biological applications.
Advances in genomics technologies in a period of radical transformation drive the field of Life Sciences. Fundamental to this genomic revolution has been the advent of Next-Generation Sequencing (NGS), which enables analysis of hundreds of millions of DNA sequences in a single experiment. Coupled with significant advances in informatics, this has underpinned a myriad of diverse applications that have already delivered rapid advances and significant impact in all fields of Life Sciences. As a result, such technologies are now a routine facet of internationally competitive research and integral to successful grant applications and high impact publications. The recent significant investment in cutting edge genomics and computational infrastructure and the aligned development of the FMHLS genomics core technology unit (GCTU) presents the opportunity for the University to become a leader in genomics.
Queen's University Belfast is committed to Equality, Diversity and Inclusion.
For more information please read our Equality and Diversity Policy.
Queen's University Belfast is registered with the Charity Commission for Northern Ireland NIC101788
VAT registration number: GB 254 7995 11